Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4767657 | 0.92 | NLRP3 (0.69) | NLRP3TSHRCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL4773228 | 0.85 | NLRP3 (0.82) | NLRP3TSHRCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL29547455 | 0.81 | SMN1; SMN2 (0.47) | NLRP3TSHRCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL13506223 | 0.80 | SMN1; SMN2 (0.68) | CYP1A2CYP2C19SMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL7378894 | 0.80 | SMN1; SMN2 (0.68) | TSHRCYP1A2CYP2C19SMN1; SMN2L3MBTL1 | |
| SCHEMBL3867996 | 0.80 | SMN1; SMN2 (0.68) | TSHRCYP1A2CYP2C19SMN1; SMN2L3MBTL1 | |
| SCHEMBL31435118 | 0.80 | NLRP3 (1.00) | NLRP3TSHRL3MBTL1ALDH1A1GAA | |
| SCHEMBL20702997 | 0.80 | NLRP3 (1.00) | NLRP3TSHRL3MBTL1ALDH1A1GAA | |
| SCHEMBL6415965 | 0.79 | NLRP3 (0.64) | NLRP3TSHRL3MBTL1ALDH1A1GAA | |
| SCHEMBL2323633 | 0.79 | SMN1; SMN2 (0.63) | TSHRCYP1A2CYP2C19SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1722796-A4 | TETRACYCLIC LACTAM DERIVATIVES AND USES THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007117289-A2 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-18 | — | — | WO | disclosed |
| EP-1722796-A2 | TETRACYCLIC LACTAM DERIVATIVES AND USES THEREOF | Inotek Pharmaceuticals Corporation (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050261288-A1 | Tetracyclic lactam derivatives and uses thereof | INOTEK PHARMACEUTICALS CORPORATION | 2005-11-24 | — | — | US | disclosed |
| WO-2005082079-A2 | TETRACYCLIC LACTAM DERIVATIVES AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261288-A1 | Tetracyclic lactam derivatives and uses thereof | PARK7, GLS, IAPP | NLRP3 547/4885TSHR 3572/4885CYP1A2 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.